522P Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials

2021 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []